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Abstract
Background:  Pharmaceuticals have made an important contribution to global reductions in
morbidity and mortality. To help save lives and improve health, it is important to be sure about
equity to access to drugs, drug efficacy, quality and safety, and rational use of drugs, which are
standardized National Drug Policy (NDP) objectives. NDP's indicators are useful to evaluate the
pharmaceutical system performance in a country. Iran has adapted a National Drug List (NDL).
Since management of drug supply in Iran takes place only for drugs that have been selected in NDL
and this list is selected by the member of Iran Drug Selecting Committee (IDSC), thus evaluation
of IDSC's decision making during last 5 years is an appropriate way to evaluate the implementation
of drug supply system in the country.
Methods:  To identify strengths and weaknesses of pharmaceutical policy formation and
implementation in Iran, four standard questionnaires of the World Health Organization (WHO)
were used. To assess the agreement between decisions of IDSC and standardized NDP indicators
in the last 5 years (1998–2002), a weighted questionnaire by nominal group technique based on the
questions that should be answered during discussion about one drug in IDSC was designed and
used.
Results: There is a totally generics based NDP with 95% local production, that provides affordable
access to drugs. The system, structures, and mechanisms were in place; however, they did not
function properly in some topics. Assessment of 59 dossiers of approved drugs for adding to NDL
during last 5 years showed that IDSC's members pay more attention to efficacy, safety, and
rationality in use rather than accessibility and affordability.
Conclusion: Revision of drug system in term of implementation of the processes to achieve NDP's
objectives is necessary to save public health. Clarification of NDP's objectives and their impact for
IDSC's members will result in improvement of the equity in access to pharmaceuticals.
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Background
The enjoyment of the highest attainable standard of
health is one of the fundamental rights of every human
being without distinction of race, religion, political belief,
and economic or social condition [1]. Everyone has the
right to a standard of living adequate for the health of
himself and of his family, including food, clothing, hous-
ing, necessary social services, and medical care [2]. Gov-
ernments and the international community have an
obligation to see the right to health progressively realized
which includes the responsibility for prevention, treat-
ment and control of disease; and the creation of condi-
tions to ensure access to health facilities, goods and
services [3]. Access to goods and services include of course
the provision of essential medicines necessary for the pre-
vention and treatment of prevalent diseases [4]. In addi-
tion, access to essential medicines is fundamental to
human rights [5].
Pharmaceuticals have made an important contribution to
global reductions in morbidity and mortality [6]. In many
developing countries, medicines represent the largest
household health expenditure. To help save lives and
improve health by closing huge gap between the potential
that essential drugs have to offer and the reality that for
millions of people medicines are unavailable, unafforda-
ble, unsafe or improperly used, World Health Organiza-
tion (WHO) is already working with a wide range of
partners to achieve this aim by drugs and medicines, and
by working with countries to ensure equity to access to
drugs, drug quality and safety, and rational use of drugs
[7]. The National Drug Policy (NDP) process brings all
interested parties; legislation/regulation, quality control,
local production, education of consumers, prescribers,
dispensers, drug evaluation, selection and registration and
rational use; together to focus political improvement and
also policy guidance, management tools, and training
materials, derived from successful drug list initiatives, do
exist.
Essential drugs are one of the tools for fighting ill health.
By increasing access to essential drugs, their safety and
their rational use, we could make the pharmaceutical
potential to improve health and save development gains
[8].
Essential drugs are high-value commodities. Their availa-
bility draws patients to health facilities, where they can
also benefit from preventive services. Moreover, if drug
procurement is efficient and transparent, the confidence
of governments and ministry in the country's health sys-
tem is increased, and provision of financial and other
resources for health system development encouraged
[7,9,10].
Since using appropriate drug list has a lot of benefits and
impact in health and economic status, it seems that eval-
uation of this list could be useful for evaluation of coun-
try-adapted policies. Iran has already adapted a National
Drug List (NDL). This list is selected by Iran Drug Select-
ing Committee (IDSC). All drug supply management
including registration, procurement, inspection, quality
control and post marketing control could be done for a
drug that it is accepted to be in Iran drug list. Thinking the
drug list is one very important element of a NDP, thus
analysis and evaluation of the IDSC's decision-making is
one necessary part of the process of evaluating the NDP.
Therefore, evaluation of IDSC's decision-making during
last 5 years may be an appropriate way to evaluate drug
supply system in Iran. Actually, these kinds of studies are
necessary to assess the organizational and political deter-
minants of the policy process; to help explain the
strengths and weaknesses identified by the indicators; and
to assist in identifying and assessing strategies to improve
pharmaceutical policy implementation.
The main study questions discussed in the study are the
followings:
1. Are the existing basic characteristics of the pharmaceu-
tical system as well structures and processes within it
ensure achievement of the main NDP goals?
2. Are the criteria used for drug selection by the IDSC for
the purposes of NDL creation compatible with the
achievement of main NDP goals?
Methods
In this study, a descriptive, explanatory, and prescriptive
objectives methodology has been designed to describe the
consequences, stakeholders, interests, and networks
involved in the NDP; to help explain how and why a par-
ticular decision was reached in the past; and to assist deci-
sion-makers in managing the politics of formulation or
implementation.
To identify strengths and weaknesses of pharmaceutical
policy formation and implementation in Iran, four stand-
ard questionnaires that were designed by WHO (Action
Program on Essential Drugs) was used (see table 1 for
more information). Questionnaires contained four cate-
gories of drug policy indicators including background
information, structural indicators, process indicators, and
outcome indicators. The indicators serve two purposes in
the research: assessment of the implementation of NDP
by measuring progress in key components (structural and
process indicators) and evaluation of the outcomes of
NDP (outcome indicators) [11].BMC International Health and Human Rights 2005, 5:5 http://www.biomedcentral.com/1472-698X/5/5
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Background information provides data on the demo-
graphic, economic, health and pharmaceutical contexts in
which drug policy is being implemented. The information
is quantitative data, at a single point in time, which was
readily available at the central level. Background informa-
tion was obtained from Iran statistics center [12], Iran
central bank [13], population report of UNICEF [14],
health status report of Iran [15], Iran drug statistics annual
report [16] and the ministry of health.
Structural indicators provide qualitative information to
assess the pharmaceutical system's capacity to achieve its
policy objectives. Questions on structural indicators were
answered as yes or no based on available information.
Process indicators provide quantitative information on
the processes by which a NDP is implemented. They
assess the degree to which activities are being effectively
implemented and the progress over time.
Outcome indicators were used to measure the results
achieved and the changes that can be attributed to the
implementation of a NDP. They measure the effects of
implementation on the overall objectives of NDP includ-
ing availability and affordability of essential drugs, drug
quality, and the rational use of drugs. Outcome indicators
were obtained from available information.
In this study, information on structural and process indi-
cators of drug allocation in the health budget and public
sector financing policy, public sector procurement proce-
dures, public sector distribution and logistics indicators
were collected from the ministry of health, Iran drug sta-
tistics annual report [16], drug regulatory affairs, and
management and planning organization of Iran. The
information of structural and process indicators of drug
pricing policy in Iran were collected from ministry of
health and drug regulatory affairs information resources.
Because of epidemiologic transition and lack of exact
prevalence of new pattern of diseases [15] and their stand-
ard treatment guidelines in Iran, calculation of the value
of the basket of drugs was impossible.
Structural and process indicators of drug allocation in
information, continuing education on drug use and
rational use of drugs were obtained from Iran drug and
poison information center, and rational drug use (RDU)/
prescribing auditing committee [17,18].
Selection of drugs for adding to list is performed in IDSC
by considering of efficacy and safety, rationality in use,
accessibility, and affordability altogether. To assess the
agreement between decisions of drug selecting committee
and standardized NDP indicators in the last 5 years
(1998–2002), an additional weighted questionnaire was
designed based on the questions that should be answered
about any drug during decision in IDSC. Questionnaire
mostly included questions about the history and docu-
mentations on efficacy and safety of drugs and also phar-
macoeconomics assessment of drugs that are usually
provided by applicants. In addition, information related
to above fields that are usually obtained from reliable and
independent sources by expert team of the secretary of
IDSC were included. Additional questions were about
identification of applicants and history of clinical trials
especially in Iran, approval record of drug by interna-
tional agencies like FDA, existence of drug standard treat-
ment guidelines (STGs), potential to be produced by local
factories, the supportive coverage umbrella like subsidiza-
tion and insurance, and also price of the nominated drug.
This information was designed in a 29-question form with
yes/no pattern. The ideal point for questionnaire could be
acquiesced with all positive answers except one. Final
decision for a new molecule to be added to NDL is per-
formed in IDSC with ten members who are selected and
authorized by minister of health. Therefore, questionnaire
was weighted by nominal group technique and by 10
members of IDSC who had mostly participated during
last 5 years in IDSC meetings. The relation between each
question and four indicators of NDP including: "efficacy
and safety", "affordability", "availability and accessibility"
and "rationality in use" have been asked and in case of
each positive relation, the member of IDSC was asked to
Table 1: WHO standardized NDP indicators
Background information
Population data
Economic data
Health status data
Health system data
Human resources
Drug sector organization
Structural and process indicators (quantitative and 
qualitative)
Legislation and regulation
Essential drugs selection and drug registration
Drug allocation in the health budget/public sector financing policy
Public sector procurement procedures
Public sector distribution and logistics
Pricing policy
Information and continuing education on drug use
Outcome indicators
Availability of essential drugs
Accessibility of essential drugs
Quality of drugs
Rational use of drugs
Reference: Brudon–Jakobowicz P, Rainhorn JD, Reich MR: Indicators 
for monitoring national drug policies, a practical manual 2nd ed. Geneva: 
World Health Organization; 1999.BMC International Health and Human Rights 2005, 5:5 http://www.biomedcentral.com/1472-698X/5/5
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give a score from 1–5 for that indicator and for negative
answer we considered the score of zero for it. Related to
the point which obtained from the IDSC's opinion, any
"yes" answer for each question could acquire scores in the
range of +1 to +5 and the answer "no" got score 0 for each
indicator. Fifty-nine drugs during 1998–2002 have been
approved by IDSC's members. Their weighted question-
naire was filled out for each medicine separately and the
results were reported by means of percentage of
agreement.
Distribution of decision makers' point of view is available
in related scattergram for interested readers (see addi-
tional file 1).
Results
Demographic, economic, health and pharmaceutical 
information
Background information about demographic, economic,
health and pharmaceutical contexts in 2002 have been
summarized in Table 2. As shown in this table, the popu-
lation of Iran is more than 66480000 with urbanization
rate of 65% and 69 years old life expectancy [12]. GNP per
capita in Iran is 1750 $US [14]. Total health budget is
12000 billions Rials. Total health expenditure is 7596 bil-
lions Rials and 5684 billions Rials is total drug expendi-
ture (8000 Rials≈ 1 $US). Data in this table also show that
the infant mortality rate is 32.1/100000 and maternal
mortality rate is 37/100000. Total number of prescribers
and pharmacists are 92548 and 10334 respectively.
Table 2 indicates that 96.1% (19.55 billions/20.348 bil-
lions) of drugs in use are produced in local pharmaceuti-
cal factories and the total number of drug manufacturing
units in the country is 57. The total number of dosage
forms in NDL is 1516 for 933 INN names that 1288 of
them are marketed by generic name in the country. There
are 6100 private pharmacies all over the country. Drug
supply management is performed centrally in Drug Regu-
latory Affairs of MOH including drug selection, registra-
tion, procurement, distribution, pricing and
subsidization, GMP control, and rational use of
medicines.
Structural and process indicators of legislation and 
regulation, drug selection and registration
Structural and process indicators of legislation and regula-
tion, essential drug selection, and drug registration in Iran
in 2002 have been summarized in Table 3. As shown in
this table, NDP has been established in Iran and updated
during last 10 years. Regulations have been issued on the
basis of drug legislation and there is a drug regulatory
authority to control registration, licensing system, the sale
and distribution of drugs. Pharmacists are legally entitled
Table 2: Background information about the demographic, economic, health and pharmaceutical contexts in 2002
Demographic data
Total population 66480000
Average annual growth of the population 1.5%
Rate of urbanization 65%
Life Expectancy 69 years
GNP per capita 1750 $US
Average annual rate of inflation 15.8%
Infant mortality rate 32.1/100000
Maternal mortality rate 37/100000
Pharmaceutical related data
Total number of prescribers 92548
Total number of pharmacists 10334
Total health budget 12000 billions Rials (1.5 billions $US)
Total health expenditure 7596 billions Rials (0.9 billions $US)
Total drug expenditure 5684 billion Rials (0.7 billions $US)
Total number of drugs in national drug list 1516
Total number of drugs under generic name sold in the country 1288
Total value of local production (numbers) 96.1% (19.55 billions/20.348 billions)
Total value of drug imports (numbers) 3.9% (797.41 millions/20.348 billions)
Total number of drug manufacturing units in the country 57
Total number of wholesalers in the country 132
Total number of private pharmacies in the country 6100
Total number of private pharmacies in the three major urban areas 1534
8000 Rials≈  1 $USBMC International Health and Human Rights 2005, 5:5 http://www.biomedcentral.com/1472-698X/5/5
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to substitute generic drugs for brand name products.
There is a quality control section, which carries out
required inspections in different stages of pharmaceuticals
production. Data show that seventy percents of total
number of drug outlets inspected was in contravention
but no sanction has been implemented for them. Iran
enjoys primary health care system (PHC). About 5000
public health centers are responsible to provide health
services to rural and underdeveloped areas including dis-
pensing of about 400 drugs freely. Value of drugs from
NDL procured in the public sector, out of total value of
drugs procured in the same sector was 27%. Of total
number of drugs, 95% was prescribed and sold from NDL.
Hundred percent of samples transferred from manufactur-
ers to the laboratory of MOH are tested. Nevertheless, it
should be noted that samples are not collected from the
market; they are collected directly from manufacturer
companies. Table 3 showed that only 910 out of 1516
dosage forms of NDL (60%) are produced locally.
Structural and process indicators of financing policy, 
procurement, distribution, logistics, and pricing policy
Structural and process indicators of drug allocation in the
health budget and public sector financing policy, public
sector procurement procedures, public sector distribution
and logistics, and pricing policy in Iran in 2002 are sum-
marized in Table 4. Existence of international nonpropri-
etary name (INN) system for listing the medicines, and
their procurements, distribution, and selling in private
pharmacies have been indicated in this table. Data indi-
cate that drug procurement unit receives required foreign
currency in less than 60 days from request to release and
the average lead-time from drug order to receipt at central
level is less than eight months. The total margin used by
wholesalers and retailers is less than 35% of the CIF (cost,
insurance, freight) price. There is a system for monitoring
drug prices regulated in the private sector. The average
lead-time required for a sample order in the last year, out
of average lead-time during the past three years decreased
Table 3: Structural and process indicators of legislation and regulation, essential drug selection, and drug registration in Iran in 2002
Is there an official national drug policy document updated in the past 10 years? +
Is there drug legislation updated in the past 10 years? +
Have regulations based on the drug legislation been issued? +
Is there a drug regulatory authority whose mandate includes registration and inspection? +
Is there a licensing system to regulate the sale of drugs (wholesalers, pharmacists,...)? +
Are pharmacists legally entitled to substitute generic drugs for brand name products? +
Are there legal provisions for penal sanctions? +
Is there a check-list for carrying out inspections in different types of pharmaceutical establishments? +
Are there any institutions where quality control is carried out? +
Is the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce used 
systematically?
+
Are there controls on drug promotion based on regulations and consistent with the WHO Ethical Criteria for Medicinal 
Drug Promotion?
+
Is there a national essential drugs list (EDL)/formulary using INN officially adopted and distributed countrywide? +
Is there an official drug committee whose duties include updating the national drugs list? +
Has the national essential drugs list /formulary been updated and distributed countrywide in the past five years? +
Do drug donations comply with the national drugs list? +
Are there formal procedures for registering drugs? +
Is there a drug registration committee? +
Is drug registration renewal required at least every five years? +
Number of drug outlets inspected, out of total number of drug outlets in the country. 100% (132/132)
Number of drug outlets in violation, out of total number of drug outlets inspected. 70% (92/132)
Number of sanctions and administrative measures implemented, out of total number of violations identified. 0%
Number of advertisements in violation of regulations on the ethical promotion of drugs, out of total number of 
advertisements monitored.
10% (5/49)
Number of sanctions implemented for advertisements in violation of regulations, out of total number of violations identified. 100% (5/5)
Value of drugs from the national drugs list procured in the public sector, out of total value of drugs procured in the same 
sector.
27% (415/1516)
Number of drugs from the national drugs list prescribed, out of total number of drugs prescribed. 95% (1440/1516)
Number of drugs from the national drugs list sold, out of total number of drugs sold. 95% (1440/1516)
Number of locally manufactured drugs sold in the country from the national drugs list, out of the total number of drugs from 
the national drugs list.
60% (910/1516)
Number of combination drugs newly registered, out of total number of newly registered drugs. 0% (0/243)
Number of registered drugs, which are banned in other countries, out of total number of registered drugs. 0% (0/243)BMC International Health and Human Rights 2005, 5:5 http://www.biomedcentral.com/1472-698X/5/5
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about 80%. The number of drugs failed from quality con-
trol testing out of the number of drugs tested was 13%.
The number of drugs beyond the expiry date out of the
total number of drugs surveyed was 0.1%.
Structural and process indicators of RDU
Structural and process indicators of drug allocation in
information and continuing education on RDU in Iran in
2002 is presented in Table 5. This table shows that the
national drug information book has been regularly pub-
lished and revised within the past five years. There is an
official continuing education system on RDU for prescrib-
ers and dispensers. There are drug information centres
that provide regular information on drugs to prescribers
and dispensers. Data of table 5 also show that there is a
national therapeutic guide with standardized treatments
but the concept of essential drugs is not part of the curric-
ula in the basic training of health personnel and there are
not therapeutic committees in the major hospitals. There
is at least one injection in 47% of total prescriptions sur-
veyed with average number of 3.6 drugs prescribed for
each patient. Antidiarrheal drugs have been prescribed for
children fewer than five in 19% of cases for treatment of
diarrhea. Average retail price of standard treatment of
pneumonia out of the average retail price of a basket of
food is 21%. No budget has been devoted for
Table 4: Structural and process indicators of drug allocation in the health budget and public sector financing policy, public sector 
procurement procedures, public sector distribution and logistics, and pricing policy in Iran in 2002
Budget and pricing
Is the drug budget spent per year more than 20% of the MOH operating budget spent per year for the last three years? +
Is the drug budget spent per capita more than US$1.00 per year for the last three years? +
Is the drug budget spent for national hospitals less than 40% of the total drug budget spent for the last three years? -
Has the drug budget spent per capita increased in the last three years? +
Are there any financing systems in addition to the drug budget that contribute to the provision of drugs in the public sector? +
Are drug prices regulated in the private sector? +
Is there at least one major incentive for selling drugs at low cost in the private sector? +
Is the total margin used by wholesalers and retailers less than 35% of the CIF price? +
Is there a system for monitoring drug prices? +
Are essential drugs sold under INN or generic name in private drug outlets? +
Average time period of payment for a sample of orders, out of average time period of payment stated in contract. 100% (7 days/7 days)
Procurement
Are drugs usually procured in the public sector through competitive tender? -
Is there a system for monitoring supplier performance? +
Are procurements done under INN? +
Does the procurement unit receive foreign currency in less than 60 days (from request to release)? +
Is procurement in the public sector limited to drugs on the national drugs list? +
Is the average lead time (from order to receipt at central level) less than eight months? +
Is procurement based on a reliable quantification of drug needs? +
Average lead time for a sample of orders in the last year, out of average lead time during the past three years. 80% (7/9)
Number of drugs/batches tested, out of number of drugs/batches procured. 0%
Number of drugs/batches that failed quality control testing, out of number of drugs/batches tested. 13% (147/1132)
Average time between order and delivery from central store to remote facilities in the last year, out of average time 
between order and delivery in the past three years.
-
Storage
Are good storage practices observed in the central procurement/distribution unit and/or major regional warehouses? +
Is the information recorded on the stock cards for drugs? +
Are the stocks for drugs within their expiry dates in the central procurement/ distribution unit and/or major regional 
warehouses?
+
Have all incoming products been physically inspected the central procurement/distribution unit and/or in the major regional 
warehouses?
+
Are drugs which are not on the national drugs list in stock in the central procurement/distribution unit and/or in the major 
regional warehouses?
-
Are 80% or more of the vehicles of the central procurement/distribution unit and/or major regional warehouses in working 
condition?
+
Are essential drugs sold under INN or generic name in private drug outlets? +
Number of drugs beyond the expiry date, out of the total number of drugs surveyed 0.1% (2/1400)BMC International Health and Human Rights 2005, 5:5 http://www.biomedcentral.com/1472-698X/5/5
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enlightening public on RDU. Of prescribers surveyed,
only 7.6% had direct access to a national drug formulary.
Only 6.9% of prescribers received independent drug bul-
letins sent by drug and poison information centres.
Number of training sessions on RDU for prescribers in the
last year out of the average number of training sessions
organized in the past three years was 13%. Number of pre-
scribers who attended at least one training session in the
last year, out of total number of prescribers surveyed was
50%.
IDSC's function
Estimation of NDP indicators including efficacy and
safety, affordability, availability and accessibility, and
RDU on approved drugs by IDSC during 1998–2002 is
shown in Figure 1. The assessment of 59 dossiers of
approved drugs for adding to NDL showed that IDSC's
members pay more attention to efficacy, safety, and
rationality in use of drugs rather than accessibility and
affordability.
Discussion
Pharmaceuticals have made an important contribution to
global reductions in morbidity and mortality [6]. Drug
supply management has a great impact in health services,
thus, evaluation, redeveloping and implementation of
drug policy has an important role in health system. Policy
guidance, management tools, and training materials are
derived from a successful drug list initiative [7]. IDSC is
responsible to establish NDL. In this study, Iran drug pol-
icy indicators were monitored by four standardized ques-
tionnaires of WHO [11].
Demographic, economic, health and pharmaceutical 
information
As shown in table 2, the population of Iran is more than
66480000 with urbanization rate of 65% and 69 years old
life expectancy [12]. GNP per capita in Iran is 1750 $US
which 5.7% of that, is usually spent for health expendi-
tures [13]. Related to demographic, economic, health, and
pharmaceutical contexts, Iran is one of the developing
countries [14]. The percentage of products in NDL which
are produced locally measures a country's self sufficiency
for supplying the most essential pharmaceutical products
[10]. Table 2 indicates that 96.1% of drugs are produced
in 57 local pharmaceutical factories. Production of drugs
domestically decreases the final price of drugs and thus
makes them more affordable and presents more feasible
and reliable procurements.
Legislation and regulation
As shown in table 3, NDP has been established in Iran and
updated in the last 10 years with inclusion of necessary
regulations and drug control legislations. By regulation of
Table 5: Structural and process indicators of drug information, continuing education on drug use, and rational use of drugs in Iran in 
2002
Is there a national publication (formulary/bulletin/manual, etc.), revised within the past five years, providing objective 
information on drug use?
+
Is there a national therapeutic guide with standardized treatments? +
Is the concept of essential drugs part of the curricula in the basic training of health personnel? -
Is there an official continuing education system on rational use of drugs for prescribers and dispensers? +
Is there a drug information unit/centre? +
Does the drug information unit/centre (or another independent body) provide regular information on drugs to 
prescribers and dispensers?
+
Are there therapeutic committees in the major hospitals? -
Are there public education campaigns on drug use? +
Is drug education included in the primary/secondary school curricula? +
Number of prescribers having direct access to a (national) drug formulary, out of total number of prescribers surveyed. 7.6% (7034/92548)
Number of training sessions on drug use for prescribers in the last year, out of average number of training sessions 
organized in the past three years.
13% (120/924)
Number of prescribers who have attended at least one training session in the last year, out of total number of 
prescribers surveyed.
50% (15203/32524)
Number of issues of independent drug bulletins published in the last year, out of average number of issues of 
independent drug bulletins published per year in the past three years.
0% (0/13)
Average number of copies of independent drug bulletins sent to prescribers, out of total number of prescribers. 6.9% (6386/92548)
Amount spent on public education campaigns on drug use, out of total amount spent on public health education 
campaigns.
0% (0/300000 $US)
Average retail price of standard treatment of pneumonia, out of the average retail price of a basket of food. 21% (2.9/13.75 $US)
Average number of drugs per prescription. 3.6
Number of prescriptions with at least one injection, out of the total number of prescriptions surveyed. 47.4% (692530/1461033)
Number of children under five with diarrhea receiving antidiarrheal drugs, out of the total number of children under five 
with diarrhea surveyed.
19% (266/1400)BMC International Health and Human Rights 2005, 5:5 http://www.biomedcentral.com/1472-698X/5/5
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national medical council, only drugs exist in NDL should
be prescribed [19]. However, this regulation has not been
implemented absolutely. About 70% of total number of
drug outlets inspected had problem of quality that may
negatively affect objectives of NDP [7]. There was no spe-
cial rule to sanction them at that duration of time but it
has now being established. Drug control and regulations
are measures of a government's capacity to implement
beneficial policies and practices in pharmaceutical man-
agement. If a government does not enforce legislation and
regulation, it means a situation where plans for pharma-
ceutical improvement exist only on paper and not in real-
ity [10]. Moreover, even if drugs are available, weak drug
regulation could mean that they are substandard, thus
spending on these medicines seems to be the major source
for poverty [8]. Almost all data have been feedback to pol-
icy makers and fortunately, improvements are observable
in some parts. In addition, some items have been taken in
the priority of many relevant committees to find reasona-
ble resolutions.
Access issues
Access to drugs is a key priority. From the consumer's
point of view, access means that drugs can be obtained
with reasonable traveling distance from health facilities
[7].
Physical access
Appropriate distribution network could provide good
accessibility for medicines within the country. Existence of
INN system for listing the medicines, and their procure-
ments, distribution, and selling in private pharmacies are
the strengths of Iran NDP (table 4) [6,10,11,20]. Private
pharmacies belong to pharmacists who are allowed to
establish their pharmacies under district regulation and
legislation of MOH. They are responsible to provide med-
icines of NDL for all patients with fixed price which
announced by MOH. They have to procure their medi-
cines from distribution centers. These centers work under
supervision of government. They procure medicines from
57 local pharmaceutical factories and 3 important drug
procurement centers. Procurement of drugs from local
industries is in priority and other pharmaceuticals import
from other countries. It should be noted that INN system
listing existing in Iran is not against the availability of pat-
ent drugs. If the patent drug is approved in NDL, it would
be subsidized too. A specific guideline has been estab-
lished in Iran for availability of drugs that are not
included in NDL. According to this guideline, the physi-
cian who prescribe a non-NDL drug should sign an
agreement and accept the responsibility for any possible
unwanted effects that might happen by use of that drug in
that specific patient. The other point is that the physician
should convince the drug regulatory affairs about not
effectiveness of the existed similar drugs in the NDL.
Finally, the drug will be imported for that patient without
any subsidy or insurance coverage only in amount of pre-
scription [19].
Pricing
Information in table 4 also indicate the existence of a
good structure and process for financing in drug supply
leading to better affordability. Potential for local
production of drugs could result in constant accessibility
of drugs with suitable prices [9,10]. It is considerable to
note that in Iran, there is a powerful subsidizing system
for drugs. Insurance companies pay about 80% of drug
price, which diminishes patient's out of pocket spending.
Evaluation of rational drug use
The evaluation of RDU in Iran is presented in table 5.
RDU means the promotion of therapeutically sound and
cost-effective use of medicines by health professionals and
consumers [7,8]. Iran was very successful in establishing
of more than 20 drug and poison information centers
around country since first 1997 and providing national
independent drug information bulletins [17] to promote
RDU. It is interesting to note that most of "standard treat-
ment guidelines" about communicable diseases in Iran
have been written [21]. Concerning epidemiologic transi-
tion [15], it is important to provide guidelines for non-
communicable illnesses specially diabetes and
Estimation of NDP indicators including efficacy and safety,  affordability, availability and accessibility, and rational use of  drugs on approved drugs by IDSC during 1998–2002 Figure 1
Estimation of NDP indicators including efficacy and 
safety, affordability, availability and accessibility, and 
rational use of drugs on approved drugs by IDSC dur-
ing 1998–2002. Number of evaluated drug dossier is 59. ES 
means efficacy and safety. RIU means rationality in use. AC 
means accessibility and AF means affordability.
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cardiovascular diseases as well as infectious diseases. Lack
of drug and treatment committee's in hospitals is indi-
cated in Table 5. To ensure proper use of drugs in thera-
peutically sounds and cost-effectiveness way, integrated
approaches between medicines and treatment manage-
ment are required [22]. There are evidences for irrational
use of drugs in Iran such as existence of at least one injec-
tion in 47% of total prescriptions surveyed and average
number of 3.6 drugs prescribed for each patient or receiv-
ing antidiarrheal drugs for children under five years old
(20%) in treatment of diarrhea [10,21,23]. On the other
hand, no budget has been devoted for cultivating public
on RDU [6,10,11] that can be a deficit for drug policy
makers.
Function of IDSC
Essential medicines are perhaps the most cost-effective
element of public health after immunization [20,24].
Regarding figure 1, the most interested factor for IDCS
members were efficacy and safety of drugs (61%). This
item is mostly experience-based and could be found in
many classic pharmacological and clinical references.
However, the existence of safe and effective medicines
could save millions of lives and prevent untold suffering
all over the world but is not enough in term of RDU [7].
In decision making of IDCS, information obtained about
experience of drug usage or approval in abroad has been
very helpful. In addition, IDSC pay enough attention to
viewpoints of health professional societies. Results of clin-
ical trials have also good impact in decision-making by
IDSC members. Worldly, the criteria for new drug
approval have been developed from experience-based to
evidence-based approach. In this regard, WHO has done
many efforts to encourage countries to provide evidence-
based NDL to implement RDU. Evidence used by WHO to
add or remove a drug might provide some basis in coun-
try-level decision-making, but in some cases, local trials
should be carried out. It should not be forgotten that exist-
ence of reliable and independent information on ques-
tioned drug [25] especially on its costs [26] are important
elements for decision-making in IDSC. Accordingly, hold-
ing adequate training workshops for IDSC members to
teach evidence-based medicine seems necessary [22].
RDU was the second frequently considered factor by deci-
sion-makers of IDSC. Existence of approved treatment
guidelines for a drug before submitting the application to
IDSC is very important. Based on the criteria examined in
the present study, only 59% of drugs were selected accord-
ing to therapeutic guidelines in the last 5 years. To pro-
mote RDU, it is necessary to provide updated STGs for
new patterns of different diseases like cardiovascular or
cancer. WHO emphasizes to provide essential life-saving
drugs developed for leading non-communicable diseases
as well as leading infectious ones [5,7,20]. Every one of
these diseases impinges detracting from health gains and
delaying progress in other areas such as education and
economic development [7,27]. Since 1999, WHO has rec-
ommended countries to design their NDL according to
national STGs [25].
Accessibility and affordability with means of 51% and
49% respectively also support that IDSC's members have
not paid enough attention in this respect. The price of
pharmaceuticals seems a substantial barrier to access for
governments and health insurers [24]. An important
point is that cost-effectiveness has been almost a forgotten
element in decision-making during the last 5 years (1998–
2002). Considering financial patterns in providing phar-
maceuticals is very important element, and if not, it will
face countries with the problem of drugs procurement
[28]. Recently two special workshops on pharmacoeco-
nomics were held for IDSC members and stakeholders.
This can be a starting point to show that importance. After
this study and finding these interesting data, new ques-
tionnaires for drug selecting has been launched and
implemented to improve the process of drug selection by
considering standardized indicators of NDP.
Finally it should be reminded that essential medicines are
those that satisfy the priority health care needs of the pop-
ulation. They are selected with due regard to public health
relevance, evidence on efficacy and safety, and compara-
tive cost-effectiveness. Essential medicines are intended to
be available within the context of functioning health sys-
tems at all times in adequate amounts, in the appropriate
dosage forms, with assured quality and adequate informa-
tion, and at a price that the individual and the community
can afford. The implementation of the concept of essen-
tial medicines is intended to be flexible and adaptable to
many different situations; exactly which medicines are
regarded as essential remains a national responsibility
[29].
Revision of drug system in Iran for implementation and
improvement of the processes to achieve NDP's objectives
is necessary to save public health. Clarification of NDP's
objectives and their impact for IDSC's members will be
helpful to improve the equity in access to
pharmaceuticals.
Conclusion
Finally, it is possible for us to answer to two main ques-
tions of this study as mentioned in introduction. Overall
results of tables 2,3,4,5 show that in Iran like most devel-
oping countries, the system, structures, and mechanisms
are in place, however, they often do not function properly,
which impeded implementation of strategies and policies
and achievement of objectives [6]. In addition, data of fig-
ure 1 shows that the criteria used for drug selection byPublish with BioMed Central    and   every 
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IDSC are 50–60% compatible with achievement of main
NDP goals. Collectively, it is concluded that drug system
in Iran is in place but needs some revisions. Further stud-
ies are required to evaluate the exact impact of drug supply
management in health in Iran.
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